ELI LILLY AND CO. news, videos and press releases - Page 5
For more news please use our advanced search feature.
ELI LILLY AND CO. - More news...
ELI LILLY AND CO. - More news...
- Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
- Investigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes
- U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit
- Lilly Completes Acquisition of ARMO BioSciences
- Lilly Declares Third-Quarter 2018 Dividend
- Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
- Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology
- Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp.
- DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial
- FDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
- FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
- Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis
- Lilly to Participate in Goldman Sachs Global Healthcare Conference
- Lilly to Participate in Jefferies Global Healthcare Conference
- Sue Mahony to Retire as President of Lilly Oncology
- Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of ARMO BioSciences, Inc. - ARMO
- Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
- Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
- WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders
- Lilly to Acquire AurKa Pharma
- Lilly to Participate in UBS Global Healthcare Conference
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ARMO BioSciences, Inc.
- Lilly Announces Agreement To Acquire ARMO BioSciences
- Lilly Declares Second-Quarter 2018 Dividend
- Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis
- Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development
- Lilly to Participate in Bank of America Merrill Lynch Health Care Conference
- Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease
- Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance
